Experimental and clinical evidence has linked cathepsin B with tumour invasion and metastasis. Cathepsin B expression is increased in many human cancers at the mRNA, protein and activity levels. In addition, cathepsin B is frequently overexpressed in premalignant lesions, an observation that associates this protease with local invasive stages of cancer. Increased expression of cathepsin B in primary cancers, and especially in preneoplastic lesions, suggests that this enzyme might have pro-apoptotic features. Expression of cathepsin B is regulated at many different levels, from gene amplification, use of alternative promoters, increased transcription and alternative splicing, to increased stability and translatability of transcripts. During the transition to malignancy, a change in the localization of cathepsin B occurs, as demonstrated by the presence of cathepsin B-containing vesicles at the cell periphery and at the basal pole of polarized cells. Due to increased expression of cathepsin B and changes in intracellular trafficking, increased secretion of procathepsin B from tumours is observed. Active cathepsin B is also secreted from tumours, a mechanism likely to be facilitated by lysosomal exocytosis or extracellular processing by surface activators. Cathepsin B is localized to caveolae on the tumour surface, where binding to the annexin II heterotetramer occurs. Activation of cathepsin B on the cell surface leads to the regulation of downstream proteolytic cascade(s).
Introduction
Tumour progression is a multi-step process that is accompanied by invasive proteolytic activity. During this process, tumour cells attach to and invade through the basement membrane and stromal extracellular matrix and migrate to distant sites. Various classes of proteolytic enzymes, including matrix metal-loproteases (e.g. gelatinases), serine proteases [urokinase-type plasminogen activator (uPA), plasmin], aspartic proteases (cathepsin D) and cysteine proteases (cathepsins B and L), have been implicated in tumour progression and invasion. The invasive proteolytic processes are complex, and depend on the sequential and simultaneous actions of many proteases. Tumour-stromal interactions add even more complexity to this system. Fibroblasts and inflammatory cells may also secrete proteolytic enzymes, and therefore aid in matrix-degrading activities. In addition, these specialized cells may also be capable of sending signals to the tumour cells to induce them to produce and secrete digestive enzymes.
An association of cathepsin B with malignant progression was reported more than two decades ago. In these early reports, cathepsin B was linked to the progression of human breast cancer [1] . Since then, increased expression, activity and secretion and changes in the localization of cathepsin B have been observed in many different tumours, including colorectal, gastric, lung and prostate tumours, melanoma, chondrosarcoma and many others [1] . In this review, we will focus on the relationship between cathepsin B expression in human cancers and malignant progression. We will discuss the molecular mechanisms responsible for the increased expression of this protease in tumours. We will characterize changes in the intracellular trafficking of cathepsin B during the transition to malignancy, and discuss the association of this enzyme with the plasma membrane. Finally, we will provide our view on the significance of cathepsin B in activating proteolytic cascade(s).
Expression of cathepsin B in advanced cancers and premalignant lesions
Cathepsin B is found in cells under normal physiological conditions, where it plays various roles in the maintenance of normal cellular metabolism. Under these normal conditions, cathepsin B is regulated at multiple levels, including transcription, post-transcriptional processing, translation, posttranslational processing and finally trafficking. In malignancy, one or more of these levels becomes misregulated, leading to increased expression and activity, and altered distribution of the enzyme within the cell.
An involvement of cathepsin B in tumour invasion has been widely demonstrated in many human carcinomas [2, 3] . Cathepsin B has both endopeptidase and exopeptidase activities [2] and is capable of degrading various components of the extracellular matrix, including type IV collagen, laminin and fibronectin [1, 2] . Cathepsin B is synthesized as an inactive proenzyme and requires activation, which may occur autocatalytically or through the action of other proteases, including cathepsins D and G, uPA, tissue-type plasminogen activator (tPA) and elastase [1] . The resulting active cathepsin B can activate other proteases. For example, pro-uPA can be activated by cathepsin B, which then leads to the conversion of plasminogen into plasmin, and subsequent degradation of many components of the stroma [4] .
Cathepsin B is not randomly expressed in tumour tissues, a finding consistent with studies suggesting that its expression is regulated by stroma-tumour interactions. In prostate cancer, increased levels of cathepsin B mRNA are found at the invasive edges of the tumours [5] . Interaction of human prostate cancer cells with matrix type I collagen leads to increased levels of the enzyme (mRNA, protein and activity), and induced secretion is observed (I. Podgorski, B. Linebaugh, M.L. Cher and B.F. Sloane, unpublished work). Similar increases in secretion upon interaction with type I collagen were reported for human breast fibroblasts [6] . Up-regulation of mRNA, protein or activity was demonstrated similarly in tumour cells at the invasive edges of colon and bladder cancers and in glioblastoma cells [3] . Increased expression of cathepsin B was also observed in fibroblasts and invading macrophages in colon and breast carcinomas [7, 8] .
Numerous studies have been dedicated to finding a correlation between cathepsin B expression/activity and stages of malignant progression. Campo et al. [7] have shown that increases in staining for cathepsin B protein are predictive of shortened patient survival. Similar correlations with progression and invasive capability were reported for gliomas and gastric carcinomas [1] . In Clara cell type carcinoma, cathepsin B staining correlated with invasion of the lymph nodes, distant metastasis and poor prognosis [3] . There is a line of evidence suggesting that cathepsin B might have a role in the transition of a preneoplastic to a neoplastic lesion. In the MCF-10 model of human breast cancer progression, diploid MCF-10A cells are spontaneously immortalized human breast epithelial cells and are non-tumorigenic. A daughter cell line, MCF-10AneoT, obtained by transfection with an activated ras oncogene, exhibits a transformed phenotype and is capable of forming preneoplastic lesions in mice, which progress to neoplasias in 30% of cases [9] . Fernandez et al. [10] observed increased expression of cathepsins B and S in the pre-invasive stages of transformed prostate epithelium. Further, amplification and overexpression of cathepsin B were reported in stage I oesophageal adenocarcinomas and 5% of Barrett's oesophagus [1] . In addition, elevated cathepsin B protein levels were detected in sera of patients with premalignant diseases of the liver and pancreas [1] . In a study by Murnane et al. [3a] , increased cathepsin B mRNA levels were observed in colorectal carcinomas when compared with normal colon tissues. More interestingly, these increases were greater for Duke's A and B tumours, which were in the process of invading through the bowel wall, than for the more advanced Duke's C and D tumours. Collectively, these results suggest that cathepsin B expression in human tumours is correlated with local invasive stages of the cancer.
Cathepsin B as a mediator of apoptotic cell death
Frequent overexpression of cathepsin B in primary tumours, and especially in premalignant stages of the disease, suggests that this enzyme may possess pro-apoptotic characteristics. In tumour development and progression, the regulation of cell survival and cell death, including apoptosis, plays an extremely important role. Mammalian organisms use programmed cell death to remove excessive, infected or dangerous cells, and as a result maintain normal cell metabolism. Molecular pathways of apoptosis are complex and not yet fully understood. Several proteolytic systems have been suggested to participate in this process, with proteases from the caspase family being the most critical [11] [12] [13] . Caspase-mediated apoptosis can be initiated in several ways. In the extrinsic pathway, cell death is provoked by tumour necrosis factor (TNF), which binds to TNF receptors (death receptors) and causes receptor oligomerization, recruitment of several intracellular proteins and subsequent activation of the cysteine protease caspase-8, also known as the initiator caspase [11, 14] . The intrinsic pathway, which is stress-induced, involves release of cytochrome c from mitochondria, induction of the cytosolic factor APAF-1 (apoptotic protease activating factor-1), apoptosome formation and once again activation of caspase-8 or -9 [11] . In the granzyme B pathway, the apoptotic signal is an effect of the delivery of the cytotoxic cell protease granzyme B to the target cell. Following the induction of initiator caspases, direct activation of executing caspases -3, -6 and -7 and subsequent killing of the cell occurs [11, 13] . This final step is common to all three pathways described above. Interestingly, in recent years it has become evident that the triggering of apoptosis is not exclusive to caspases. Many laboratories have demonstrated that lysosomes and their associated non-caspase proteases, including cathepsins B and D, are essential downstream effectors of caspases [11, 12, 15] . The importance of lysosomes in cell death has been suggested by several sources. Lysosomal rupture has been readily associated with oxidative stress. Accordingly, oxidative-stress-induced apoptosis caused by hydrogen peroxide and serum deprivation have been linked to such ruptures of lysosomes [14, 16] . Lysosomal integrity is often compromised in pathological states as well as during the normal aging process, thus resulting in leakage of proteases into the cytosol [11] . It has been suggested that such leakage may be involved in the activation of caspases [14] . For instance, cathepsin B has been shown to activate pro-inflammatory caspase-11 and -1 [17] . Interestingly, some studies have shown that apoptosis can occur in the absolute absence of caspases [12, 18] One of the first reports indicating the involvement of cathepsins in the death pathways came from Roberts et al. [19] , who suggested a role for cathepsin B in bile salt-induced apoptosis in rat hepatocytes. The same group has shown in subsequent studies that cathepsin B was not an activator of caspases in these cells, but that cathepsin B activity was caspase-dependent [20] . Therefore cathepsin B seems to act downstream of caspases in this particular apoptotic pathway.
The apoptotic role of cathepsin B in hepatocytes was elucidated further by Guicciardi et al. [17] , who investigated the role of cathepsin B in TNFmediated killing. In their study, treatment of mouse hepatocytes with actinomycin D and TNF␣ resulted in release of cathepsin B into the cytosol and subsequent induction of enzyme activity. Release of cathepsin B into the cytosol also was induced by active caspase-2 or -8, and was reduced in hepatocytes from cathepsin B-deficient mice. Interestingly, during treatment of wild-type hepatocytes with TNF␣, release of mitochondrial cytochrome c into the cytosol was observed and the time course of this release was similar to that of cathepsin B. Cytochrome c release was reduced in cathepsin B-deficient cells, which places cathepsin B upstream of mitochondria in this apoptotic pathway [17] . One molecular mechanism by which cathepsin B may affect mitochondria and the release of cytochrome c is via selective proteolysis of Bid [14] . Bid is a Bcl-2 family member, which upon activation (cleavage) by caspase-8 or granzyme B induces cytochrome c release. In the study of Stoka et al. [14] , recombinant Bid was cleaved by a lysosomal extract, which led to induced cytochrome c release from mitochondria. In addition, levels of cytochrome c were similar to those released by the caspase-8-activated Bid.
Additional evidence for an involvement of cathepsin B in TNF-mediated killing was demonstrated by Foghsgaard et al. [12] . This study utilized WEHI-S fibrosarcoma cells and ME180as cervix carcinoma cells, both of which are sensitive to TNF-mediated cell death. In WEHI-S cells, cathepsin B was shown to be the dominant execution protease even in the presence of a pan-caspase inhibitor. In ME180as cells, cathepsin B acted as a downstream effector of receptor-activated caspases. The involvement of cathepsin B in various apoptotic pathways is summarized in Table 1 .
The molecular identity of all mediators of programmed cell death remains to be elucidated. It is now clear that a single death receptor can trigger multiple mechanisms leading to cell death. Evidence now clearly suggests that both caspase-dependent and caspase-independent apoptotic pathways exist. It is possible that the caspase-independent pathway is a back-up system in tumour cells, in which caspase-dependent mechanisms have been impaired due to mutations or overexpression of survival proteins [21] . Cathepsin B seems to be involved in both upstream and downstream death signals, suggesting the importance of this protease in all stages of apoptosis. Tumour cells generally have increased levels of cathepsin B. Interestingly, a death receptor-triggered, cathepsin B-dependent apoptosis pathway seems to be more prominent in tumour cells than in primary cells [12] . On the other hand, natural cysteine protease inhibitors (e.g. cystatin A) may inhibit the apoptotic process due to inactivation of the effector species. This possibility is supported by reports of the aggressiveness of tumours overexpressing cystatin A [12] . It is therefore possible that lysosomal proteases, especially cathepsin B, play dual roles in malignant progression, and that the entire process depends on a delicate balance between the protease and its inhibitor, as well as between pro-apoptotic and pro-invasive properties of the protease. It is also becoming evident that a variety of cells participate in malignant transition.
Molecular mechanisms behind cathepsin B expression in tumours
Whether at a certain stage of the disease cathepsin B exhibits pro-apoptotic or invasion-promoting characteristics might be the result of various genetic rearrangements and mutations. Cathepsin B is synthesized as a preproenzyme in the rough endoplasmic reticulum and, after being co-translationally glycosylated, moves through the Golgi complex to lysosomes. Trafficking to lysosomes can occur via a mannose 6-phosphate receptor (MPR)-mediated pathway or an MPR-independent pathway [22] . Multiple levels of regulation exist during the synthesis and processing of the enzyme, including transcription, maturation of RNA, translation, trafficking and interaction with natural inhibitors. Cathepsin B expression, activity and localization in tumour cells may be modulated at any one or many of these levels. The cathepsin B gene is a single-copy gene mapping to chromosome 8p22 [3, 22] . The protease has a housekeeping-gene-type promoter that is TATAand CAAT-less and GC-rich [3] . This promoter has a single transcription start site and multiple binding sites that include USF (upstream stimulatory factor), six closely spaced Sp1 and four Ets binding sites. The promoter activity is upregulated by the binding of transcription factors ( [3] ; S. Yan and B.F. Sloane, unpublished work). The 5Ј-flanking region of the cathepsin B gene contains additional transcription start sites [23] , which suggests the existence of more than one promoter. Alternative promoters have also been demonstrated in the mouse [24] . Perhaps the different promoter regions of the cathepsin B gene are regulated independently depending on the microenvironment and the presence or relative levels of transcription factors or other regulatory species.
Transcription factors, including Sp1 family members, appear to play an important role in the regulation of cathepsin B gene expression. The activity of Sp1 itself is modulated by various regulatory proteins and nuclear factors, regulation that could be critical for cathepsin B expression and activity [25] . In addition, it has been shown that Sp1-regulated promoters may be regulated by members of various transduction pathways, such as c-Fos tyrosine-protein kinase or cAMP-dependent protein kinase [26] Another transcription factor implicated in the regulation of proteases important for malignant progression is Ets1, a member of the Ets superfamily. Expression of Ets1 has been demonstrated to correlate positively with invasive phenotypes of lung carcinomas and breast carcinoma cell lines [26] . Ets1 has been implicated in the regulation of uPA, a serine protease known to play a role in motility and tumour invasion [26] . In addition, Ets1 has been reported to regulate the transcription of some matrix metalloproteinases (MMPs), i.e. MMP-1 and MMP-3 [27] . Furthermore, correlations between mRNA levels of Ets1 and another metalloproteinase, MMP-7, have been suggested to be predictive of the metastatic progression of lung cancer [28] and a marker of poor prognosis in ovarian carcinoma [29] . A role for Ets1 in two important malignant processes, apoptosis and angiogenesis, has also been suggested [30, 31] . Transcription of cathepsin B is most likely to be mediated by multiple transcription factors, and it is possible that the interplay between Sp1 and Ets1 regulates cathepsin B expression. Such synergistic Sp1/Ets1 activity has already been demonstrated to regulate the promoter activity of megakaryocytic and parathyroid hormone-related genes [26] .
The increased expression of cathepsin B mRNA in tumours is often associated with gene amplification. A novel 8p22-8p23 amplicon, corresponding to the cathepsin B gene locus, was recently identified and linked to the overexpression of cathepsin B in oesophageal adenocarcinoma [1] . Amplified and overexpressed cathepsin B was observed in premalignant lesions (Barrett's oesophagus), suggesting a role for cathepsin B in malignant progression. This is likely to be a regulatory mechanism in other tumours, as suggested by amplification of the cathepsin B gene in transformed rat ovarian cells [1] .
Cathepsin B is a product of a single gene, yet several transcript species of this enzyme have been reported [32] . Multiple transcripts can be a result of alternative splicing, a regulatory mechanism mediating cathepsin B expression in arthritis and cancer [22] . Six mRNA transcript species are produced due to alternative splicing of the 5Ј-untranslated region, whereas splicing of the 5Ј-translated region produces two additional transcripts [22] . A truncated form of procathepsin B is produced from the latter two transcripts. Lacking a signal propeptide, such a protein cannot enter the vesicular pathway. Thus translation from such transcript species may affect the cellular localization of cathepsin B and account for its presence in the cytoplasm [22, 32] . Diffuse cytoplasmic staining for cathepsin B was observed in COS cells transfected with the truncated form of the proenzyme [32] . Changes in the post-translational processing of primary transcripts can lead to the production of more stable mRNA species, and ultimately to increased levels of cathepsin B mRNA and protein.
In some cases, elevated mRNA levels result from an increased rate of transcription caused by the altered levels of transcription factors [33] .
Various studies have demonstrated changes in cathepsin B mRNA expression during differentiation. An increase in mRNA and protein levels has been observed in human U937 promonocytic cells induced to differentiate by granulocyte/macrophage colony-stimulating factor or phorbol ester [34] . Cathepsin B mRNA expression in the HL-60 leukaemia cell line is induced in a dose-dependent manner by inducers of both monocytic and granulocytic differentiation [34] . An increase in the level of cathepsin B transcripts occurs before the achievement of the differentiated phenotype, suggesting that the above inducers regulate gene expression by directly or indirectly triggering certain signal transduction cascades. Cathepsin B mRNA expression can therefore be regulated at both the transcriptional and post-transcriptional levels [34] .
The increased levels of cathepsin B protein and activity observed in many cancer cell lines and tumours [3, 23] do not always result from elevated levels of mRNA. In human breast epithelial cells transfected with the c-Ha-ras oncogene, increased levels of cathepsin B protein and activity along with changes in trafficking and an association with the plasma membrane are observed, while mRNA levels are unchanged [35] . A similar pattern is observed in colon epithelial cells transfected with K-ras4B val12 , suggesting post-translational regulation of cathepsin B expression [36] .
Localized expression and secretion of cathepsin B in human cancer
Under normal conditions, cathepsin B is associated with lysosomes, where as a housekeeping enzyme it is involved mainly in protein degradation. A small fraction of the proenzyme (5-10%) can be secreted from normal cells [1, 22] . For malignant tumours to invade, proteolytic activity is required in the vicinity of infiltrating cells and at the invasive edge of the tumour. Accordingly, localization of cathepsin B in cancer cells changes from perinuclear lysosomes to vesicles in the peripheral cytoplasm and cell processes and to the plasma membrane. The presence of cathepsin B on the surface of tumour cells has been demonstrated for B16a melanoma and glioma cells [37] and Ki-ras-expressing colorectal carcinoma cells (D. Cavallo-Medved and B.F. Sloane, unpublished work). A striking change in localization of the enzyme during malignant transition has been demonstrated in the MCF-10A breast cancer model [38] . By means of immunogold staining, the presence of cathepsin B on the surface, in perinuclear vesicles and in cell processes of MCF-10AneoT cells was shown, a phenomenon not observed in the parental MCF-10A cells. Interestingly, the breast carcinoma cell lines MCF-7 and BT-20 showed staining patterns similar to those of MCF-10AneoT cells, and cathepsin B was localized to the interior basal and outer basal surface of the cells [38] .
Localized expression of cathepsin B has been extensively demonstrated in urinary bladder carcinomas, glioblastomas, and colon and prostate carcinomas [1] [2] [3] . Expression of cathepsin B in tumour cells at the invading edge as well as in the surrounding stroma [7] usually correlates with increased secretion of the enzyme and subsequent degradation of the extracellular matrix [1] . Cathepsin B has been shown to degrade extracellular matrix proteins, including laminin, collagen IV, fibronectin [1] and, recently, tenascin-C [39] . Interestingly, in gastric cancer, increased expression of surface cathepsin B is correlated with decreased levels of laminin and a higher invasive potential [40] .
Cancer cells and tumours secrete both pro-and mature forms of cathepsin B, as demonstrated in breast and colon carcinomas, gliomas and murine melanomas [1, 22] . Procathepsin B is generally secreted constitutively by an MPR pathway. Saturation of MPRs due to increased expression of cathepsin B in cancers will most probably result in increased secretion of proenzyme. Such a mechanism has already been demonstrated for the secretion of procathepsin D [41] . Increased secretion of procathepsin B can also occur due to defective or down-regulated MPRs, as observed in an invasive murine SCC-VII squamous carcinoma cell line and in pancreatic islets of transgenic mice, both of which are deficient in MPRs [42, 43] .
The secretion of active forms of cathepsin B occurs via inducible pathways, mechanisms for which are still being investigated. It is possible that the activators on the cell surface process cathepsin B extracellularly. Alternatively, the enzyme may be processed through the classical lysosomal pathway and secreted by a retrograde mechanism. Lysosomal exocytosis and secretion of mature active cathepsin B has been observed in rat exocrine pancreas due to the fusion of lysosomes with secretory granules [32] . It is well known that catalytic activity of cathepsin B is pH-dependent and complex [32] . The distribution and secretion of active enzyme also depends on extracellular pH. In particular, in B16 melanoma cells, slightly acidic conditions induce the migration of cathepsin B-containing vesicles to the cell periphery, resulting in enhanced secretion [32] . Movement of lysosomes to the cell surface upon a reduction in pH has also been demonstrated in macrophages and fibroblasts [44] . In this case, lysosomes move to the cell surface on microtubules, a process linked to the movement of cathepsin B to the surface of MCF-10AneoT cells [9] . Growth of tumour cells on extracellular matrices led to the observation that large acidic vesicles are formed and participate in matrix digestion [32] . A correlation between the invasiveness of various cancer lines and their ability to phago-cytose extracellular matrix has been shown by Coopman et al. [45] . Recently, exocytosis of cathepsin B-containing vesicles was observed upon stimulation of MCF-10Aneo cells with phorbol ester [46] . In this case the participation of cathepsin B in a proteolytic cascade involving uPA and plasmin(ogen) was demonstrated, a cascade implicated in metastatic progression.
Association of cathepsin B with the cell surface
In addition to proteases secreted from tumour cells and tumour-associated cells, surface-bound proteases are important players in local proteolysis. Many proteases implicated in extracellular matrix degradation and tumour progression, including tPA, plasmin(ogen), uPA, membrane-type MMPs and membrane-type serine proteases, are integral membrane proteins or are associated with receptors/binding proteins on the tumour cell surface [47, 48] . Recently we have demonstrated that p11, one of the two subunits of annexin II heterotetramer (AIIt), is a binding partner for procathepsin B on the tumour cell surface [49] . Interestingly, expression of AIIt has been demonstrated to be highly up-regulated in many tumours and, similarly to cathepsin B, parallels malignancy [49] . Moreover, AIIt binds to, among others, matrix type I collagen, tPA, plasmin(ogen) and tenascin C [49] . Association of AIIt with tenascin C is particularly attractive, since we have shown recently that cathepsin B is capable of degrading this extracellular matrix protein [39] . In addition, both proteins are overexpressed in malignant anaplastic astrocytomas and glioblastomas, and can also be detected in neovessels, suggesting their participation in angiogenesis. Since tenascin C has been shown to be highly overexpressed at the stroma-tumour interface of various tumours [39] , interaction of this protein with cathepsin B in vivo may be critical to metastatic progression.
An interesting aspect of the association of cathepsin B with the cell surface is the recent finding that this protease is localized to caveolae (lipid raft) fractions isolated from colorectal carcinoma cells (D. Cavallo-Medved and B.F. Sloane, unpublished work). Caveolae are believed to be involved in cell surface proteolysis. Enhanced plasminogen activation has been demonstrated as a result of clustering of uPA and its receptor in caveolae [50] . In addition, AIIt has also been shown to localize to caveolae (D. Cavallo-Medved and B.F. Sloane, unpublished work). Caveolin-1, the major structural component of caveolae, regulates many signalling molecules involved in cell adhesion, migration and invasion [51] , and has been reported to possess tumour suppressor characteristics [52] . Caveolin-1 is overexpressed in various tumours of the prostate, colon, breast and bladder and, interestingly, an involvement in the metastatic progression of prostate cancer has been attributed to its anti-apoptotic activities [53] . In addition, Ki-ras-expressing HCT-116 colorectal carcinoma cells overexpress caveolin-1, as compared with HKh-2 cells in which the Ki-ras allele was disrupted by homologous recombination (D. Cavallo-Medved and B.F. Sloane, unpublished work). In parallel with caveolin expression, increased localization of cathepsin B to caveolae has been observed in HCT-116 cells, changes that were correlated with increased invasiveness. Collectively, these data suggest the possibility of functional interplay between caveolin-1 and cathepsin B on the tumour cell surface. Perhaps caveolae serve as a centre of proteolytic activity, where various components of proteolytic cascades co-cluster, interact, and ultimately execute their functions in metastatic progression.
Conclusions, and significance of cathepsin B in malignant progression
Cancer is a complex disease that results from multiple genetic alterations, and involves a functional interplay between various cell types and signalling molecules expressed by them. An important factor in metastasis is the ability of tumour cells to degrade and move through extracellular matrices. Matrix degradation is co-operatively influenced by various members of proteolytic cascade(s), and each member may have an important, but distinct, role(s) in tumour growth and invasion. Our current view of the interactions of cathepsin B with the various systems implicated in malignant progression is depicted in Figure 1 .
The tumour environment consists of not only tumour cells, but also stromal and inflammatory cells and components of the extracellular matrix, and it is now well recognized that all of these contribute to malignancy. There is no doubt that the roles that cathepsin B plays in tumour progression need to be elucidated further, especially with regard to interactions with other proteolytic enzymes and regulation of cathepsin B expression. Evidence gathered so far, however, leaves no doubt about the association of this enzyme with tumour progression, especially with the transition from premalignant lesions to invasive ones. This work was supported by National Institutes of Health (NIH) grants CA 36481 and CA 56586, and DOD grants PC991261 and BC013005. Due to a limitation on the number of references, we have cited mainly review articles, and therefore apologize to the authors of many important primary papers, which have not been cited.
